APA

Gurbel P. A., Bergmeijer T. O., Tantry U. S., ten Berg J. M., Angiolillo D. J., James S., Lindahl T. L., Svensson P., Jakubowski J. A., Brown P. B., Duvvuru S., Sundseth S., Walker J. R., Small D., Moser B. A., Winters K. J. & Erlinge D. (20150615). The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. : Thrombosis and haemostasis.

Chicago

Gurbel P A, Bergmeijer T O, Tantry U S, ten Berg J M, Angiolillo D J, James S, Lindahl T L, Svensson P, Jakubowski J A, Brown P B, Duvvuru S, Sundseth S, Walker J R, Small D, Moser B A, Winters K J and Erlinge D. 20150615. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. : Thrombosis and haemostasis.

Harvard

Gurbel P. A., Bergmeijer T. O., Tantry U. S., ten Berg J. M., Angiolillo D. J., James S., Lindahl T. L., Svensson P., Jakubowski J. A., Brown P. B., Duvvuru S., Sundseth S., Walker J. R., Small D., Moser B. A., Winters K. J. and Erlinge D. (20150615). The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. : Thrombosis and haemostasis.

MLA

Gurbel P A, Bergmeijer T O, Tantry U S, ten Berg J M, Angiolillo D J, James S, Lindahl T L, Svensson P, Jakubowski J A, Brown P B, Duvvuru S, Sundseth S, Walker J R, Small D, Moser B A, Winters K J and Erlinge D. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. : Thrombosis and haemostasis. 20150615.